The former Lonza division LSI, a specialty chemicals company active in Microbial Control Solutions (MCS) and Specialty Products Solutions (SPS), will operate under the...

Swiss CDMO Lonza and Danish clinical-stage pharma Allarity Therapeutics have agreed to develop and manufacture anti-cancer therapy dovitinib. The companies are aiming to...

Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process...

Swiss CDMO Lonza plans to invest an undisclosed sum to establish drug product manufacturing capabilities at its site in Guangzhou, China. The investment in the central...

Lonza has completed the carve-out of its Specialty Ingredients business as LSI and appointed a management team led by CEO Mark Doyle, a former DuPont and DowDuPont chief...

Lonza is investing 20 million Swiss francs in an expansion of its API development and manufacturing facility at Nansha, China. The Basel-based CDMO said the expanded...

Swiss CDMO Lonza is collaborating with Swedish pharma SelectImmune to develop processes for NlpD, a novel immunotherapy protein that could provide an alternative to...

As it ramps up production on three continents, US Covid-19 vaccine manufacturer Moderna is expanding its collaborations with CDMO suppliers in Europe, the US and Asia. At...